1.63
Aclaris Therapeutics Inc 주식(ACRS)의 최신 뉴스
Earnings Update: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Just Reported And Analysts Are Boosting Their Estimates - simplywall.st
Earnings Beat: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - uk.finance.yahoo.com
Aclaris Therapeutics Reports Q2 2025 Earnings, Highlights Clinical Advancements and Financial Metrics. - AInvest
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Beats Revenue Estimates - MSN
Aclaris Therapeutics Reports Q2 Loss, Highlights Progress in Immuno-Dermatology Pipeline - MSN
Aclaris Reports Positive Phase 2a Results for ATI-2138 in Atopic Dermatitis Trial - MSN
Aclaris Therapeutics Reports Q2 2025 Results and Updates - TipRanks
Ati Inc. shares rise 2.39% premarket after Aclaris Therapeutics reported positive clinical results from Phase 2a trial of ITK/JAK3 inhibitor ATI-2138. - AInvest
Aclaris: Q2 Earnings Snapshot - Chron
Aclaris Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Aclaris Therapeutics reports Q2 EPS (13c), consensus (13c) - TipRanks
Aclaris Therapeutics Inc earnings beat by $0.01, revenue topped estimates - Investing.com Australia
Aclaris Therapeutics shares rise 3.23% premarket after reporting Q2 earnings that met Wall Street expectations. - AInvest
Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Leerink Partners Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $7 - 富途牛牛
Relief Rally in Aclaris Therapeutics Inc. Stock — Can It HoldFree Membership Group - beatles.ru
What drives Aclaris Therapeutics Inc. stock priceMaximize your returns with smart trade entries - Jammu Links News
Aclaris Therapeutics Taps Veteran Biotech Leader Roland Kolbeck as New Chief Scientific Officer - MSN
How many analysts rate Aclaris Therapeutics Inc. as a “Buy”Invest confidently with professional market insights - Jammu Links News
What are Aclaris Therapeutics Inc. company’s key revenue driversTriple-digit profit margins - Jammu Links News
Is Aclaris Therapeutics Inc. a growth stock or a value stockDiscover undervalued opportunities early - Jammu Links News
What is the dividend policy of Aclaris Therapeutics Inc. stockCapitalize on emerging market trends - Jammu Links News
Is Aclaris Therapeutics Inc. a good long term investmentCapitalize on market trends before they peak - Jammu Links News
What analysts say about Aclaris Therapeutics Inc. stockMarket-leading growth rates - Jammu Links News
What is the risk reward ratio of investing in Aclaris Therapeutics Inc. stockUnmatched profit potential - Jammu Links News
What are the latest earnings results for Aclaris Therapeutics Inc.Discover market opportunities with expert help - Jammu Links News
What catalysts could drive Aclaris Therapeutics Inc. stock higher in 2025Unlock powerful market analysis and alerts - Jammu Links News
Aclaris Therapeutics Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
How volatile is Aclaris Therapeutics Inc. stock compared to the marketBreakout Stocks Watchlist That Work - jammulinksnews.com
Is it the right time to buy Aclaris Therapeutics Inc. stockDaily Trading Report For Consistent Profits - Jammu Links News
Is Aclaris Therapeutics Inc. stock bottoming outTechnical Screener for High Growth Stocks - Newser
Is a relief rally coming for Aclaris Therapeutics Inc. holdersTechnical Stock Breakout Predictions Signal Entry Points - metal.it
Will Aclaris Therapeutics Inc. outperform the marketRisk Shielded Trade Watch with Analysis - Newser
Analysts Boost Healthcare Stocks: Aclaris Therapeutics and Nuvation Bio - AInvest
Aclaris Therapeutics Inc. Breaks Below Key Support LevelQuick Gain Stock Watch With Indicators Reviewed - metal.it
Aclaris Therapeutics (ACRS) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Market reaction to Aclaris Therapeutics Inc.’s recent newsEntry Alert Based on Volume Spikes Detected - metal.it
Stock Market Today: US Future Edge Higher Ahead Of FOMC Decision—Meta, Microsoft Earnings In Focus - Benzinga
Momentum divergence signals in Aclaris Therapeutics Inc. chartAI Model Forecasting Reversal and Breakout Zones - Newser
Aclaris Therapeutics Stock Spikes In After‑Hours Session Following Major Announcement - Benzinga
Aclaris Therapeutics Announces Positive Top-Line Results - GlobeNewswire
Aclaris Therapeutics stock soars after positive Phase 2a trial results By Investing.com - Investing.com South Africa
Aclaris Therapeutics stock soars after positive Phase 2a trial results - Investing.com Australia
Aclaris Therapeutics Announces Positive Phase 2a Trial Results - TipRanks
자본화:
|
볼륨(24시간):